Investigational drug · Phase 2
SPT-300
Also called: LYT-300, GlyphAllo, Glyph Allopregnanolone
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "SPT-300"
First trial start
2025
Jun 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPT-300", any sponsor or status.
Conditions studied
As listed on its trial records.
- Major Depressive Disorder (MDD)
- Major Depressive Disorder With Anxious Distress
Approved drugs for the same conditions: Depression (major depressive disorder) · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "SPT-300" as an intervention, largest first.
- An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)Enrolling by invitation
Seaport TherapeuticsIndustry
NCT07161700 · 360 participants (planned) · Start Sep 2, 2025 · Primary completion May 2027
Drug: SPT-300 · For: Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress
Sites: Chino, California; Garden Grove, California; Glendale, California · 46 sites in all
- A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)Pivotal-lookingRecruiting
Seaport TherapeuticsIndustry
NCT07065240 · 360 participants (planned) · Start Jun 19, 2025 · Primary completion Mar 2027
Drug: SPT-300; Placebo · For: Major Depressive Disorder (MDD); Major Depressive Disorder With Anxious Distress
Sites: Chino, California; Garden Grove, California; Glendale, California · 62 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- Acute anxiety states in emergency neuropsychiatry: diagnostic boundaries, time-sensitive mechanisms, and rapid-acting therapeutic strategies.
Wei Y, Shi Z, Shen Y · Expert Rev Neurother 2026
- An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans.
Simpson JS, Quach T, Han S, et al. · Sci Transl Med 2026
- GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors.
Cerne R, Lippa A, Poe MM, et al. · Pharmacol Ther 2022
- The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders.
Witkin JM, Lippa A, Smith JL, et al. · Pharmacol Biochem Behav 2022
Also in development for Major Depressive Disorder (MDD)
- KH607Phase 34 trials
Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Major Depressive Disorder (MDD), Postpartum Depressive Disorder
- CYB003Phase 33 trials
Cybin IRL Limited · Major Depressive Disorder, Major Depressive Disorder (MDD), Depression in Adults
- Bupropion Sustained-ReleasePhase 31 trial
CSPC Ouyi Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)
- DT-101Phase 22 trials
Draig Therapeutics Ltd · Major Depressive Disorder (MDD)
- ACP-211Phase 21 trial
ACADIA Pharmaceuticals Inc. · Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
- NH102Phase 21 trial
Jiangsu Nhwa Pharmaceutical Co., Ltd. · Major Depressive Disorder (MDD)
- SPN-821Phase 21 trial
Supernus Pharmaceuticals, Inc. · Major Depressive Disorder (MDD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.